Clinical trials: Refractory Aggressive B-cell Lymphomas, open to volunteers
Non-Hodgkin Lymphoma, B-cell
MEN1703 (SEL24) to Treat Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma (JASPIS-01)
The goal of the study is to assess the safety and anti-lymphoma activity of MEN1703 (Dapolsertib hydrochloride) when given as a single-agent or combined with glofitamab to patients with relapsed/refractory (R/R) aggressive B-cell…
- Trial name
- JASPIS-01 (NCT06534437)
- Testing
- MEN1703, Glofitamab
- Where
- 35 sites in France, Poland and 2 more
- Volunteers
- 178 people
- Sponsor
- Ryvu Therapeutics SA
B Cell Lymphoma, NHL, Adult
SynKIR-310 for Relapsed/Refractory B-NHL
This first-in-human (FIH) trial is designed to assess the safety, feasibility and preliminary efficacy of a single intravenous (IV) dose of SynKIR-310 administered to participants with relapsed/refractory B-NHL.
- Conditions
- B Cell Lymphoma, NHL, Adult, Mantle Cell Lymphoma, Relapsed Non-Hodgkin Lymphoma
- Trial name
- NCT06544265
- Testing
- SynKIR-310
- Where
- 5 sites in United States
- Volunteers
- 36 people
- Sponsor
- Verismo Therapeutics
R/R Aggressive B-cell Lymphoma
An Open and Dose-escalation Early Clinical Study of CD19 and CD20 CAR-T Cell Therapy for Relapsed or Refractory Aggressive B-cell Lymphoma
To observe the efficacy and safety of dual-target chimeric antigen receptor T cells in the treatment of refractory or relapsed aggressive B-cell lymphoma
- Trial name
- NCT07344818
- Testing
- CAR-T cell therapy
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Peking University People's Hospital
Aggressive Diffuse Large B-cell Lymphoma, High-grade B-cell Lymphoma (HGBL)
Combining Loncastuximab Tesirine and Epcoritamab in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
This is a phase II study designed to evaluate the toxicity and efficacy of the combination of loncastuximab tesirine and epcoritamab in patients with relapsed/refractory aggressive B-cell lymphoma.
- Conditions
- Aggressive Diffuse Large B-cell Lymphoma, High-grade B-cell Lymphoma (HGBL), Follicular Lymphoma (FL) Grade 3B
- Trial name
- CLEAR (NCT07197307)
- Testing
- Loncastuximab Tesirine and Epcoritamab
- Where
- 34 sites in Germany
- Volunteers
- 120 people
- Sponsor
- Universität Münster
Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia, Relapsed or Refractory B Cell Non-Hodgkin Lymphoma
A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL)
This is a Phase 1b/2 study to evaluate the safety and efficacy of autologous T cells engineered with a chimeric antigen receptor (CAR) targeting cluster of differentiation (CD)19 in pediatric patients with relapsed or refractory…
- Trial name
- NCT06173518
- Testing
- AUTO1
- Where
- 14 sites in United States, Spain and 1 more
- Volunteers
- 30 people
- Sponsor
- Autolus Limited
Aggressive B-Cell Non-Hodgkin's Lymphoma (NHL)
Integrated Radiotherapy-optimized ASCT Sequential CAR-T Therapy for Patients With Relapsed and Refractory B-NHL
This study aims to investigate a novel therapeutic strategy of integrated radiotherapy before autologous stem cell transplantation (ASCT) sequential chimeric antigen receptor T-cell(CAR-T) therapy for patients with…
- Trial name
- NCT07059741
- Testing
- integrated low-dose RT with reduced SEAM/TB conditioning before ASCT sequential CAR-T, integrated high-dose RT with reduced SEAM/TB conditioning before ASCT sequential CAR-T
- Where
- China
- Volunteers
- 20 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Lymphoma, B-cell, Aggressive Non-Hodgkin (B-NHL), AML (Acute Myelogenous Leukemia)
The Application of CAR-T Cell Therapy in Relapsed and Refractory Malignant Hematologic Tumors
This study is an open, single-arm, prospective, Phase I/II clinical study using "3+3" dose escalation and dose expansion to investigate the safety, maximum tolerated dose, in vivo pharmacokinetic profile, and preliminary efficacy…
- Conditions
- Lymphoma, B-cell, Aggressive Non-Hodgkin (B-NHL), AML (Acute Myelogenous Leukemia), Myeloma Multiple, B-ALL
- Trial name
- CAR-T (NCT06911710)
- Testing
- CAR-T Cells infusion（CAR2219,CAR2019, CAR19 etc）
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Tianjin Medical University General Hospital
Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Grade 3b Follicular Lymphoma
Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma
This phase Ib/II trial evaluates the safety, optimal dose, and efficacy of the combination of epcoritamab and ibrutinib in treating patients with aggressive B-cell non-Hodgkin lymphoma that has come back (relapsed) or responded…
- Conditions
- Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Grade 3b Follicular Lymphoma, Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, Recurrent High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements
- Trial name
- NCT06536049
- Testing
- Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy
- Where
- 3 sites in United States
- Volunteers
- 38 people
- Sponsor
- Yazeed Sawalha
Relapsed/Refractory Aggressive B-Cell Lymphoma
Clinical Study of SYS6055 Injection in Participants With Relapsed/Refractory Aggressive B-Cell Lymphoma
This is a Phase I/II clinical study conducted in participants with relapsed/refractory aggressive B-cell lymphoma. The study aims to evaluate the safety, tolerability, pharmacokinetic characteristics and preliminary efficacy of…
- Trial name
- NCT07476066
- Testing
- SYS6055
- Volunteers
- 374 people
- Sponsor
- Beijing Kangchuanglian Biopharmaceutical Technology Research Co., Ltd
Multiple Myeloma in Relapse, Multiple Myeloma, Refractory
Early Palliative Care for Patients With Multiple Myeloma and Aggressive Lymphoma
Patients with multiple myeloma experience a wide range of physical and psychological symptoms from the time of their diagnosis. Meanwhile, patients with aggressive lymphomas undergo unpredictable illness courses, resulting in…
- Conditions
- Multiple Myeloma in Relapse, Multiple Myeloma, Refractory, Multiple Myeloma Stage III, Multiple Myeloma Progression
- Trial name
- EPC-MM+L (NCT06485076)
- Testing
- Early Palliative Care
- Where
- Canada
- Volunteers
- 144 people, healthy volunteers welcome
- Sponsor
- University Health Network, Toronto
AIDS-Related Diffuse Large B-cell Lymphoma, AIDS-Related Non-Hodgkin Lymphoma
Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin Lymphoma
This phase I trial evaluates the side effects and usefulness of axicabtagene clioleucel (a CAR-T therapy) and find out what effect, if any, it has on treating patients with HIV-associated aggressive B-cell non-Hodgkin lymphoma…
- Conditions
- AIDS-Related Diffuse Large B-cell Lymphoma, AIDS-Related Non-Hodgkin Lymphoma, HIV Infection, Recurrent Diffuse Large B-Cell Lymphoma
- Trial name
- NCT05077527
- Testing
- Axicabtagene Ciloleucel, Cyclophosphamide, Fludarabine
- Where
- 7 sites in United States
- Volunteers
- 20 people
- Sponsor
- AIDS Malignancy Consortium
Refractory Non-Hodgkin Lymphoma, Relapsed Non-Hodgkin Lymphoma
First in Human Study of the Infusion of ARI0003 Cells in Relapsed/Refractory to Treatment B-cell Aggressive Lymphoma
ths study consist in testing a CAR T therapy (ARI0003 cells (antiCD19 and antiBCMA) in patients suffering relapsed NHL (that means that symptoms of NHL reappeared ) or refractory (that means that they did not respond to other…
- Trial name
- CARTD-BG-1 (NCT06097455)
- Testing
- ARI0003
- Where
- 7 sites in Spain
- Volunteers
- 40 people
- Sponsor
- Fundacion Clinic per a la Recerca Biomédica
Large B-Cell Lymphoma With IRF4 Rearrangement, Recurrent Aggressive B-Cell Non-Hodgkin Lymphoma
Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell Therapy
This phase II trial tests the effectiveness of golcadomide and rituximab as bridging treatment before chimeric antigen receptor (CAR) T-cell therapy in patients with aggressive B-cell non-Hodgkin lymphoma that has come back after…
- Conditions
- Large B-Cell Lymphoma With IRF4 Rearrangement, Recurrent Aggressive B-Cell Non-Hodgkin Lymphoma, Recurrent ALK-Positive Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma Activated B-Cell Type
- Trial name
- NCT06834373
- Testing
- Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy
- Where
- 7 sites in United States
- Volunteers
- 41 people
- Sponsor
- Mayo Clinic
Lymphoma
CD19/CD22 CAR-T Consolidation in R/R Aggressive B-Cell Lymphoma After Second-Line Therapy
The purpose of this study is to determine the efficacy and safety of CD22/CD19-targeted CAR-T cell immunotherapy as consolidation therapy after second-line treatment in patients with high-risk aggressive B-cell lymphoma.
- Trial name
- NCT07779018
- Testing
- CD22/CD19 CAR-T cell immunotherapy
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Liping Dou
Relapsed or Refractory Aggressive B-cell Lymphoma
Bispecific Antibody-Based Salvage Therapy Followed by CAR-T ± ASCT in R/R Aggressive B-Cell Lymphoma
This study consists of two sequential treatment phases. In the first phase, patients with r/r aggressive B-NHL receive two cycles of glofitamab ± investigator-selected agents.
- Trial name
- NCT06996132
- Testing
- Glofitamab, Chimeric Antigen Receptor T Cells (CAR-T)
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Relapsed or Refractory Aggressive B-Cell Non-Hodgkins Lymphoma
Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL
This Phase II trial evaluates the optimization of the cytokine release syndrome (CRS) profile for glofitamab in combination with gemcitabine and oxaliplatin (Glofit-GemOx) followed by glofitamab monotherapy treatment regimen (Cohort…
- Trial name
- NCT06806033
- Testing
- Obinutuzumab, Glofitamab, Gemcitabine
- Where
- 53 sites in United States, Australia and 5 more
- Volunteers
- 130 people
- Sponsor
- Hoffmann-La Roche
Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia
Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)
Subjects on this study have a type of lymph gland cancer called Non-Hodgkin Lymphoma, acute lymphocytic leukemia, or chronic Lymphocytic Leukemia (these diseases will be referred to as "lymphoma" or "leukemia").
- Conditions
- Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, Acute Lymphocytic Leukemia
- Trial name
- SAGAN (NCT01853631)
- Testing
- Dose Escalation Phase:CD19.CAR/28 and CD19.CAR/28137 T cells, Expansion Phase: CD19.CAR/28 and CD19.CAR/28137 T cells
- Where
- 2 sites in United States
- Volunteers
- 64 people
- Sponsor
- Baylor College of Medicine
Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma
Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
This is a Phase 1/2, multi-center, open-label study evaluating the safety and efficacy of rondecabtagene autoleucel (ronde-cel) also known as LYL314, a dual-targeting chimeric antigen receptor (CAR) targeting cluster of…
- Conditions
- Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Large B-cell Lymphoma
- Trial name
- NCT05826535
- Testing
- Rondecabtagene autoleucel (ronde-cel), Fludarabine, Cyclophosphamide
- Where
- 35 sites in United States, Australia
- Volunteers
- 270 people
- Sponsor
- Lyell Immunopharma, Inc.
Lymphoma, B-cell Lymphomas
GLORY: Glofit-GemOx With Liso-Cel For Lymphoma
The goal of this clinical trial is to assess the clinical efficacy of bridging therapy with glofitamab/gemcitabine/oxaliplatin (Glofit-GemOx) followed by lisocabtagene maraleucel (liso-cel) in relapsed/refractory large B-cell…
- Conditions
- Lymphoma, B-cell Lymphomas, Relapsed/Refractory Large B-cell Lymphoma, Large B-cell Lymphoma
- Trial name
- GLORY (NCT07711483)
- Testing
- Obinutuzumab, Glofitamab, Gemcitabine & oxaliplatin
- Where
- 2 sites in United States
- Volunteers
- 56 people
- Sponsor
- Massachusetts General Hospital
Diffuse Large B-cell Lymphoma Refractory, Refractory Primary Mediastinal Large B-Cell Lymphoma
Golcadomide Post-CAR T-cell in R/R Aggressive Large B-cell Lymphoma Patients With High Risk of Relapse
This study is an open-label, multicenter, proof of concept, phase 2 trial. Patients will be recruited over 18 months. Safety analysis will be performed with a stop of the enrollment after 3 patients have either 1 complete…
- Conditions
- Diffuse Large B-cell Lymphoma Refractory, Refractory Primary Mediastinal Large B-Cell Lymphoma, Refractory Transformed B-cell Non-Hodgkin Lymphoma, Refractory High Grade B-Cell Lymphoma
- Trial name
- NCT06271057
- Testing
- golcadomide
- Where
- 13 sites in France
- Volunteers
- 65 people
- Sponsor
- The Lymphoma Academic Research Organisation